BiotechTube

TNX-1300 (Injection) + Placebo (Injection)

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cocaine Use

Conditions

Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction

Trial Timeline

Aug 16, 2024 → Apr 21, 2025

NCT ID
NCT06045793

About TNX-1300 (Injection) + Placebo (Injection)

TNX-1300 (Injection) + Placebo (Injection) is a phase 2 stage product being developed by Tonix Pharmaceuticals for Cocaine Use. The current trial status is terminated. This product is registered under clinical trial identifier NCT06045793. Target conditions include Cocaine Use, Cocaine Intoxication, Cocaine Toxicity.

What happened to similar drugs?

1 of 2 similar drugs in Cocaine Use were approved

Approved (1) Terminated (0) Active (1)
🔄Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
✅quetiapineAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06045793Phase 2Terminated

Competing Products

13 competing products in Cocaine Use

See all competitors
ProductCompanyStageHype Score
Topiramate + Cognitive Behavioral Therapy + Placebo + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
36
TopiramateJohnson & JohnsonPhase 2
35
quetiapineAstraZenecaApproved
43
quetiapine fumarate + Matched PlaceboAstraZenecaPre-clinical
26
AFQ056 + PlaceboNovartisPhase 1
21
AFQ056 + PlaceboNovartisPhase 2
35
ALKS 33-BUP + ALKS 33 + PlaceboAlkermesPhase 1
26
VIVITROL (Naltrexone extended-release injectable suspension) + PlaceboAlkermesPhase 2
32
vigabatrin + placeboCatalyst PharmaceuticalsPhase 2
29
Vigabatrin + Matching PlaceboCatalyst PharmaceuticalsPhase 2/3
32
Vigabatrin + PlaceboCatalyst PharmaceuticalsPhase 2
29
CPP-115 + PlaceboCatalyst PharmaceuticalsPhase 1
23
TNX-1300Tonix PharmaceuticalsPhase 2
17